Business
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP),
About this update from Disc Medicine, Inc.
[{"type":"text","content":"Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its hematology portfolio at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025. “As we progress toward major company milestones in the second half of 2025, this year’s EHA presentations showcase steady progress across our pipeline,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “We plan to share data from the HELIOS long-term extension trial, further supporting bitopertin’s potential profile as the first disease-modifying treatment for EPP. We’ll also present additional durability data and new analyses from the Phase 1b study of DISC-0974 in patients with MF anemia, along with new data from DISC-3405 in healthy volunteers that supports its progression into a Phase 2 study in polycythemia vera in the first half of this year and its broader potential in diseases of iron overload.” Management will host a call to review the presented data on June 16 at 8:00 am ET. Please register for the event on the Events and Presentations page of Disc’s website (https://ir.discmedicine.com/) Details of Presentations and Abstracts The full abstracts are now available through the EHA conference website. Pursuant to Disc Medicine practice, the abstracts published today contain previously presented data, and new data and analyses are reserved for presentation at the conference. Bitopertin Poster Presentations: Abstract Number: PS2210Title: Results from the HELIOS Study: A Phase 2, Open-Label, Long-Term Extension Study of Bitopertin in Erythropoietic ProtoporphyriaDate / Time: Saturday, June 14, 6:30 pm CEST / 12:30 pm E...